Cancer Treatment Reviews
Volume 31, Issue 4 , Pages 283-302 , June 2005

Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: A systematic review

  • M. Trudeau

      Affiliations

    • Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue (T-Wing), Toronto, Ont., Canada M4N 3M5
    • Corresponding Author InformationCorresponding author. Present address: c/o Breast Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-Based Care, Courthouse T-27 Building, 3rd Floor, McMaster University, 1280 Main Street West, Hamilton, Ont., Canada L8S 4L8. Tel.: +1 905 525 9140(x)22149; fax: +1 905 522 7681
    • ,
  • S.E. Sinclair

      Affiliations

    • Program in Evidence-based Care, McMaster University, 1280 Main Street West, Hamilton, Ont., Canada L8S 4L8
    • ,
  • M. Clemons

      Affiliations

    • Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue (T-Wing), Toronto, Ont., Canada M4N 3M5
    • ,
  • members of the Breast Cancer Disease Site Group

      Affiliations

    • Please see the Program in Evidence-based Care section of the Cancer Care Ontario Web site http://www.cancercare.on.ca/access_PEBC.htm for a complete list of current Disease Site Group members.

References 

  1. Bear HD. Indications for neoadjuvant chemotherapy for breast cancer. Semin Oncol. 1998;25(2 Suppl 3):3–12
  2. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer. 1990;66(6 Suppl):1387–1391
  3. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16(1):93–100
  4. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460–469
  5. Goble S, Bear HD. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am. 2003;83(4):943–971
  6. Valero V, Buzdar AU, McNeese M, Singletary E, Hortobagyi GN. Primary chemotherapy in the treatment of breast cancer: the University of Texas M.D. Anderson Cancer Center experience. Clin Breast Cancer. 2002;3(Suppl 2):S63–S68
  7. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer. 1992;69(11):2849–2852
  8. Mauriac L, Durand M, Avril A, Dilhuydy JM. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3cm. Results of a randomized trial in a single centre. Ann Oncol. 1991;2(5):347–354
  9. Cunningham JD, Weiss SE, Ahmed S, et al. The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer. Cancer Invest. 1998;16(2):80–86
  10. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant vs. adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994;30A(5):645–652
  11. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431–1439
  12. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976–983
  13. Nabholtz J, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC(docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study [abstract]. Proc Am Soc Clin Oncol. 2002;21(1):36a
  14. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003;290(4):495–501
  15. Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999;17(11):3412–3417
  16. Pouillart P, Fumoleau P, Romieu G, et al. Final results of a phase II randomized, parallel study of doxorubicin/cyclophosphamide(AC) and doxorubicin/Taxol [trade] (paclitaxel) (AT) as neoadjuvant treatment of local-regional breast cancer [abstract]. Proc Am Soc Clin Oncol. 1999;18(1):73a
  17. Malamos N, Kosmas C, Antonopoulos J, et al. Prospective randomized study of neoadjuvant chemotherapy (NACT) with paclitaxel/epirubicin (PE) versus fluorouracil/epirubicin/cyclophosphamide (FEC) in operable stage II-IIIA breast cancer (BC) [abstract]. Ann Oncol. 1998;9(4):22
  18. Evans TRJ, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer [Internet slide presentation]. In: 2004 ASCO virtual meeting 2004; 22(July 15 Suppl 14S): A521. www.asco.org/ac/1,1003,_12-002643-00_18-0026-00_19-001449,00.asp [accessed 22.08.04]
  19. Lee HG, Lee JJ, Jung K-H, Kwon Y, Shin EH, Chung K-W, et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis [Internet abstract]. In: ASCO annual meeting proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22(July 15 Suppl 14S):A607. http://www.asco.org/ac/1,1003,_12-002643-00_18-0026-00_19-00254,00.asp [accessed 05.10.04]
  20. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165–4174
  21. Hutcheon AW, Heys SD, Miller ID. Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomized controlled trial [abstract]. Breast Cancer Res Treat. 2001;69:298
  22. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer:3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3(Suppl 2):S69–S74
  23. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20(6):1456–1466
  24. Hutcheon AW, Heys SD, Sarkar TK, et al. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial [abstract]. Breast Cancer Res Treat. 2003;82(Suppl 1):S6
  25. von Minckwitz G, Raab GBJU, Gerber B, et al. In vivo chemosensitivity-adapted neoadjuvant chemotherapy (docetaxel–doxorubicin–cyclophosphamide followed by vinorelbine-capecitabine salvage therapy) in patients with primary breast cancer: results of the GEPAR-TRIO randomized pilot study [abstract]. Breast Cancer Res Treat. 2003;82(Suppl 1):S54
  26. Bouzid K, Vinholes J, Salas F, et al. A phase III trial of taxotere and doxorubicin (AT) versus 5-fluorouracil, doxorubicin and cyclophosphamide in patients with unresectable locally advanced breast cancer: an interim analysis [abstract]. Eur J Cancer. 2001;37(Suppl 6):S167
  27. Luporsi E, Vanlemmens L, Coudert B, Mayer F, Bonneterre J. 6 cycles of FEC100 vs6 cycles of epirubicin–docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (pts): preliminary results of a randomized phase II trial of Girec S01. Proc Am Soc Clin Oncol. 2000;19:92a
  28. Gianni L, Baselga J, Eirmann W, et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease [abstract]. Proc Am Soc Clin Oncol. 2002;21(1):34a
  29. Comella G, Thomas R, Capasso I, Silvestro P, Russo A, Petrillo A, et al. Comparison of weekly cisplatin–epirubicin–paclitaxel (PET) with triweekly epirubicin–paclitaxel (ET) in locally advanced breast cancer (LABC). SICOG 9908 phase III trial [Internet abstract]. In: ASCO annual meeting proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(Jul 15 Suppl 14S):A511. http://www.asco.org/ac/1,1003,_12-002643-00_18-0026-00_19-001389,00.asp [accessed 11.05.04]
  30. Stearns V, Singh B, Tsangaris T, et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res. 2003;9(1):124–133
  31. Untch M, Konecny G, Ditsch N, et al. Dose-dense sequential epirubicin–paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study [abstract]. Proc Am Soc Clin Oncol. 2002;21(1):34a
  32. Romieu G, Tubiana-Hulin M, Fumoleau P, et al. A multicenter randomized phase II study of 4 or6 cycles of adriamycin/Taxol (paclitaxel) (AT) as neoadjuvant treatment of breast cancer (BC). Ann Oncol. 2002;13(Suppl 5):33
  33. Green MC, Buzdar AU, Smith TL, et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC-final results of a prospective phase III randomized trial [abstract]. Proc Am Soc Clin Oncol. 2002;21(1):35a
  34. Steger GG, Kubista E, Hausmaninger H, Gnat M, Tausch C, Lang A, et al. 6 vs. 3 cycles of epirubicin/docetaxel+G-CSF in operable breast cancer: results of ABCSG-14 [abstract]. 2004;22(July 15 Suppl 14S):A553. www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-002962,00.asp [accessed 22.08.04]
  35. Miller KD, McCaskill-Stevens W, Sisk J, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol. 1999;17(10):3033–3037
  36. Chollet P, Amat S, Penault-Llorca F, et al. Neoadjuvant docetaxel: 4-year survival outcomes and prognostic factors in patients with operable breast cancer (BC) [abstract]. Proc Am Soc Clin Oncol. 2003;22:48
  37. Monfardini S, Brunner K, Crowther D. Evaluation of the cancer patient and the response to treatment. UICC manual of adult and pediatric medical oncology. Berlin, Germany: Springer; 1987;p. 22–38
  38. Buzdar AU, Singletary SE, Valero V, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002;8(5):1073–1079
  39. Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180(3):297–306
  40. Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16(3):223–228
  41. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320–327

PII: S0305-7372(05)00057-5

doi: 10.1016/j.ctrv.2005.03.007

Cancer Treatment Reviews
Volume 31, Issue 4 , Pages 283-302 , June 2005

Article Tools